Jpmorgan Chase & CO Relmada Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RLMD
# of Institutions
56Shares Held
5.44MCall Options Held
0Put Options Held
0-
Driehaus Capital Management LLC Chicago, IL740KShares$1.43 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA619KShares$1.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$1.11 Million0.0% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD397KShares$765,2720.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA364KShares$702,6680.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $55.2M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...